IC
PASG icon

Ikarian Capital’s Passage Bio PASG Stock Holding History

Ikarian Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$535K Buy
+68,124
New +$705K 0.04% 125
2022
Q2 		– Sell
-3,593
Closed -$223K – 185
2022
Q1 		$223K Buy
3,593
+201
+6% +$16.6K 0.03% 161
2021
Q4 		$431K Hold
3,392
– – 0.06% 135
2021
Q3 		$677K Sell
3,392
-3,901
-53% -$930K 0.05% 176
2021
Q2 		$1.93M Hold
7,293
– – 0.16% 133
2021
Q1 		$2.55M Buy
7,293
+458
+7% +$196K 0.09% 186
2020
Q4 		$3.5M Buy
+6,835
New +$2.74M 0.15% 117

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ikarian Capital's PASG Position: Q1 2026 in Review

Ikarian Capital opened a new position in Passage Bio (PASG) in Q1 2026: 68,124 shares worth $535K. The stake represents 0.04% of the portfolio and ranks #125 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in PASG as recently as Q1 2022.

Ikarian Capital first reported a position in PASG in Q4 2020 and has held it in 7 quarters since. The position peaked at $3.5M in Q4 2020. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Ikarian Capital held 68,124 shares of Passage Bio worth $535K as of Q1 2026.
  • Passage Bio was a new Ikarian Capital position in Q1 2026.
  • Passage Bio made up 0.04% of Ikarian Capital's portfolio in Q1 2026, its #125 holding.
  • Ikarian Capital first reported a position in Passage Bio in Q4 2020 and has held it in 7 quarters since.
  • Ikarian Capital's Passage Bio position peaked at $3.5M in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.